314
Participants
Start Date
November 1, 2022
Primary Completion Date
September 30, 2027
Study Completion Date
December 31, 2027
Zatolmilast/ BPN14770
25mg zatolmilast/BPN14770 (Adults) or 15 mg zatolmilast/BPN14770 (Adolescents \<43 kg)
Icahn School of Medicine at Mount Sinai, New York
Clinic for Special Children, Strasburg
Suburban Research Associates, Media
Kennedy Krieger Institute, Baltimore
Greenwood Genetic Center, Greenville
Emory University School of Medicine, Atlanta
University of Miami, Miami
Cincinnati Children's Hospital Medical Center, Cincinnati
Rush University Medical Center, Chicago
University of Kansas Medical Center, Kansas City
Children's Hospital Colorado, Aurora
University of Utah and Primary Children's Hospital, Salt Lake City
Amnova Clinical Research, Irvine
Thompson Autism & Neurodevelopment Center - CHOC, Orange
MIND Institute UC Davis Medical Center, Sacramento
Boston Children's Hospital, Boston
U Mass, Worcester
Lead Sponsor
Tetra Discovery Partners
INDUSTRY